N1-Methylpseudouridine

• UNSPSC Description:

  N1-methyl-pseudouridine (1-Methylpseudouridine), a methylpseudouridine, outperforms 5 mC and 5 mC/N1-methyl-pseudouridine in translation. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density[1].

• Target Antigen:

  DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog

• Type:

  Oligonucleotides

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/n1-methylpseudouridine.html

• Purity:

  99.97

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)

• Smiles:

  OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](C(C(N2)=O)=CN(C)C2=O)O1

• Molecular Weight:

  258.23

• References & Citations:

  [1]Svitkin YV, et al. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 2017 Jun 2;45(10):6023-6036.|[2]Andries O, et al. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015 Nov 10;217:337-44.|[3]Nance KD, Meier JL. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent Sci. 2021;7(5):748-756.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  13860-38-3